Day One Biopharmaceuticals (NASDAQ:DAWN) Issues Earnings Results, Beats Estimates By $0.58 EPS

Day One Biopharmaceuticals (NASDAQ:DAWN - Get Free Report) released its earnings results on Wednesday. The company reported $0.38 EPS for the quarter, beating the consensus estimate of ($0.20) by $0.58, Briefing.com reports. The business had revenue of $93.76 million for the quarter, compared to the consensus estimate of $15.05 million. During the same period in the prior year, the business posted ($0.54) EPS.

Day One Biopharmaceuticals Trading Up 1.7 %

Day One Biopharmaceuticals stock traded up $0.25 during trading hours on Thursday, hitting $14.72. 4,070,943 shares of the stock traded hands, compared to its average volume of 936,002. The firm's 50-day moving average price is $14.18 and its two-hundred day moving average price is $14.39. The company has a market cap of $1.29 billion, a PE ratio of -7.55 and a beta of -1.51. Day One Biopharmaceuticals has a one year low of $10.90 and a one year high of $18.07.

Insider Buying and Selling at Day One Biopharmaceuticals

In other Day One Biopharmaceuticals news, insider Samuel C. Blackman sold 30,000 shares of Day One Biopharmaceuticals stock in a transaction that occurred on Tuesday, September 10th. The stock was sold at an average price of $14.22, for a total transaction of $426,600.00. Following the sale, the insider now directly owns 1,097,535 shares of the company's stock, valued at approximately $15,606,947.70. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. In other news, insider Samuel C. Blackman sold 30,000 shares of the business's stock in a transaction that occurred on Tuesday, September 10th. The stock was sold at an average price of $14.22, for a total value of $426,600.00. Following the sale, the insider now directly owns 1,097,535 shares of the company's stock, valued at $15,606,947.70. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Jeremy Bender sold 10,681 shares of the business's stock in a transaction that occurred on Friday, August 16th. The stock was sold at an average price of $14.00, for a total value of $149,534.00. Following the completion of the sale, the chief executive officer now directly owns 98,932 shares in the company, valued at approximately $1,385,048. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 48,748 shares of company stock valued at $689,072. 8.40% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on DAWN. Piper Sandler restated an "overweight" rating and issued a $40.00 price objective on shares of Day One Biopharmaceuticals in a research report on Monday, July 8th. Wedbush reissued an "outperform" rating and issued a $33.00 target price on shares of Day One Biopharmaceuticals in a research note on Thursday, July 25th. Bank of America raised Day One Biopharmaceuticals from an "underperform" rating to a "buy" rating and raised their target price for the stock from $11.00 to $24.00 in a research note on Thursday, August 1st. HC Wainwright reissued a "buy" rating and issued a $40.00 target price on shares of Day One Biopharmaceuticals in a research note on Thursday. Finally, JPMorgan Chase & Co. cut their target price on Day One Biopharmaceuticals from $38.00 to $36.00 and set an "overweight" rating on the stock in a research note on Tuesday, August 6th. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $35.71.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.